Navigation Links
ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector
Date:8/6/2009

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today the introduction of the Res-Q(TM) 60 BMC ("Res-Q") System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.

The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP(TM) MarrowXpress(TM) ("MXP") System, a laboratory device also used to collect stem cells from bone marrow.

The Company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies ("Celling"), a subsidiary of SpineSmith, LLC. Celling is a leading distributor of orthopedic products based in Texas and also serves as a distributor of the MXP System. In a separate press release today, ThermoGenesis and Celling announced an expanded collaboration between the two firms. Separately, the Company plans to expand Res-Q's applications into the cardiovascular and other non-orthopedic regenerative medicine markets.

"We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

"We are delighted to be participating in the launch of the Res-Q System with ThermoGenesis," said Kevin Dunworth, Chief Executive Officer of SpineSmith, LLC. "The device represents a high level of innovative technology and we look forward to building upon our early success with the MXP," he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

  • The BioArchive((R)) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP((R)) AutoXpress(TM) Platform ("AXP"), a proprietary family of automated devices that includes the AXP and the MXP((TM)) MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
  • The Res-Q((TM)) 60 BMC ("Res-Q"), a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
  • The CryoSeal((R) )FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

    ThermoGenesis Corp.
    Web site:http://www.thermogenesis.com
    Contact: Investor Relations
    +1-916-858-5107, or
    ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Appoints Chief Executive Officer J. Melville (Mel) Engle to Board of Directors
2. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2009 Results on May 6, 2009
3. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
4. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
5. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
6. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
7. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
8. ThermoGenesis Reports First Quarter 2009 Results
9. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
10. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
11. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/9/2017)... ... ... Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a week-long ... BTF,s Mobile MRI Unit – a 70 Ft. ... brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign to ...
Breaking Medicine Technology: